For drugs delivered to patients in crystalline form, the physical properties of the pharmaceutical intermediates or active pharmaceutical ingredient (API) including crystal form, size and shape have the potential to impact bioperformance, particularly for low-solubility compounds, where the rate-limiting-step in drug uptake may be the dissolution of the API in the gut. These physical properties of the API are often controlled in the final API crystallization step. http://www.purestchem.com/phar....maceutical-intermedi